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Clinical Trial Arrhythmias II 
Huah Calkins Robert Hoyt, Mark A. Wood, Emile Daoud. Gregory M. Ayers, Neal Kay, 
Johns Hopkins Medical Institutions, Baltimore, MD Tuesday, April 01, 2003, Noon-2:00 p.m. 
Background: Pulmonary vein stenosis is a known complication of RF ablation of atrial McCormick Place, Hall A 
fibrillation (AF). Cryoablatlon represents an alternative energy source that may prevent Presentation Hour: I:00 p.m.-2:OO p.m 
this complication. The purpose of this multicenter clinical trial is to test the safety and efli- 
cacy of dryoablation orthe pulmonary vein ostia for treatment of AF. 
Methods: Fourteen patients (12 males, 5828 yrs) with drug refractory paroxysmal AF 
1186-3 
- 
Effects of Intravenous lbutilide on the Complexity of 
underwent catheter ablation using a 1 OFr cryo-ablation system (CryoCor, Inc). All pulmo- Activation and the Incidence of Reentry During 
nary vein (PV) ostia with PV potentials were targeted for ablation. Pulmonary vein venog Ventricular Fibrillation in Pigs 
raphy was performed prior to and following the ablation procedure. 
Results: Thirty-nine veins were determined to have PV potentials and were targeted for 
cryoablation. Successful isolation was achieved in 38 veins (96%). A mean of 7.4 -+ 2.9 
applications were required per vein. The mean ablation time was 293 +18 minutes and 
the mean fluoro time was 1342105 minutes. No pulmonary vein stenosis was observed. 
There were no complications associated with the cryo ablation procedureConclusions: 
The acute results of this multicenter clinical trial demonstate that electrical isolation of the 
PV osiia can be accomplished safely and effectively with cryoablation. No PV stenosis 
was observed. Enrollment of additional patients and long-term clinical follow-up is now 
underway. 
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846-6 Efficacy of Circumferential Pulmonary Vein Ablation in 
Patients With Atrial Fibrillation and Associated Heart 
Failure 
Carlo Pappone, Salvatore Rosanio, Giuseppe Augello, Simone Gulletta, Cosimo 
Dicandia, Patrizio Mazzone, Ale&a Pappone, Gabriele Paglino, Mario Pittalis. Gabriele 
Vicedomini. San Raffaele University Hospital, Milan, Italy 
Background: Atrial fibrillation (AF) is common in patients (pts) with heart failure (HF) 
and adversely affects the prognosis. The electroanatomical substrate responsible for AF 
in this population may be different from AF pts without HF. Circumferential pulmonary 
vein ablation (CPVA) with CART0 guidance has emerged as a cure for AF, its target 
being both PV trigger isolation and arrhythmogenic substrate modification. The outcome 
of this therapy in AF pts with associated HF is unknown. 
Objective: To assess the CPVA outcome in AF pts with associated HF. 
Methods: Between June 1999 and July 2001, 648 pts with paroxysmal (n=419) or 
chronic (n=229) AF (79% M, age 59*9 years, AF duration 7&.5 years; 59% with struc- 
tural heart diseasa) underwent CPVA. Pts were followed-up with serial visits, Halter 
recordings and echocardiography. 
Results: Compared to those without HF (n=525, 81%), AF pts with HF (n=123, 19%: 
ejection fractton [EF]<40%: New York Heart Association [NYHA] class 2.8+0.7) were 
older, had larger left atrial diameter and a greater magnitude of mitral regurgitation and 
left ventricular size (PcO.01 for all comparisons). After 16~6 months freedom from AF 
without antiarrhythmics was 79% in HF pts and 63% in those without (P=NS). Ablation 
resulted in a significant EF and NYHA class improvement in HF pts (from 31*9% to 
44+6%, p<O.Ol; and from 2.8~0.7 to l&0.9, P<O.Ol, respectively) but not in those with- 
out, whereas left atrial diameter was reduced in both groups. A subgroup of 255 pts 
underwent the Short Form-36 Health Survey (SF-36) to quantify perceived quality of life 
(QoL) pre-RF and 6 and 12 months post-RF. Pre-RF, SF-36 scores were significantly 
lower (P.zO.05) in pts with HF (n=72) than in pts with no HF (n=183), reflecting significant 
impairment in well-being, physical and social functioning, and mental health. Post-CPVA, 
QoL improved significantly at 6 months and 1 year on all scales in both groups except for 
bodily pain, which was not decreased pre-CPVA. 
Conclusions: In AF pts. concomitant HF does not adversely affect ablation success. In 
this high-risk population, the procedure improves cardiac function and QoL measures, 
and may potentially reduce future HF-related adverse events. 
Hao Jian Huang, Jack M. Rogers, Dennis L. Rollins, William M. Smith, Raymond E. 
Ideker, University of Alabama at Birmingham, Birmingham, AL 
Background Wa hypothesized that prolongation of ventricular refractoriness caused by 
the class Ill antiarrhythmic drug lbutilide would decrease both the incidence of reentry 
and the complexity of activation during ventricular fibrillation (VF). Methods A plaque 
with 504 unipolar electrodes (2 mm resolution) was sutured onto the epicardium of the 
right ventricular free wall to map VF induced by a 9.volt battery in 6 pigs. VF activation 
panerns, the defibrillation threshold (DFT), effective refractory period (ERP), and 90% of 
action potential duration (APD,) were determined before and after an intravenous bolus 
of 100 p@kg ibutilide. During ERP and APD measurements, the heart was paced with a 
pair of wire electrodes inserted into the left ventricular subepicardium. ERP was deter- 
mined from the pacing electrodes using an 5152 protocol. APD,, was measured from 
monophasic action potentials recorded by an endocardial catheter at the left ventricular 
apex. Results After ibutilide, the ERP and APD, increased by 24% and 19%, respac- 
tively. and the DFT energy decreased by 13% (PcO.05). VF activation patterns analyzed 
with automated algorithms also changed: the mean number of wavefronts, activation 
rate, percent wavefronts that collided with other wavefronts, and the incidence of reentry 
(the number of reentrant wavefronts divided by the number of all wavefronts) decreased 
after ibutilide by 19%. 21%, 22%, and 86%, respectively (PcO.05). The mean perimeter 
and duration of reentrant wavefronts increased by 44% and 43%, respectively (P<O.O5). 
However, the percent of wavefronts that blocked increased by 25% after ibutilide 
(P<O.O5).Conclusions The Increase in ERP and APDgr, caused by intravenous ibutilide 
is accompanied by a marked decrease in the incidence of reentry during VF. While ibutil- 
ide increased the organization of activation sequences during VF by several measures, 
i.e., the decrease in the number of wavefronts, activation rate, and percent wavefronts 
that collided with other wavefronts. it decreased organization by one measure, i.e., the 
increase in the incidence of conduction block. 
1186-4 Cardiac Connexin43 Gap Junction Channels Participate 
in the Establishment of Membrane Potential and Cell 
Growth 
Asif Sewan~, Carolina Vasquez, Edward Berbari, Alonso P. Moreno, Indiana University 
School of Medicine. Krannert Institute of Cardiology, Indianapolis. IN, Purdue University, 
Indianapolis, IN 
Introduction: Cell-to-cell communication via gap junctions constitutes the basis of elec- 
trotonic coupling among cardiac myocytes. Gap junctions are also involved in the mainte- 
nance of metabolic and structural properties of the tissues. We are reporting here that in 
Normal Rat Kidney (NRK) cells, connected through protein connexin43 channels, cell-to- 
call communication is required for the establishment of membrane potential and cell 
growth, representing a suitable model to study the mechanisms involved in these pro- 
cesses. 
Methods: NRK cells were plated on petri dishes and grown in culture media. Cell resting 
membrane potential (RMP) was calculated using the whole cell voltage clamp technique. 
Cell growth was determined after trypsin treatment and counting the number of cells 
under a hemacytometer. 
Results: RMP was related to the number of cells coupled together in a cluster following 
an exponential relationship. Isolated or cells clustered in sets of 3 or less expressed a 
RMP of 0.4iO.19 mV. n=5. In contrast, RMP in confluent cell cultures changed signifi- 
cantly to -59r0.23 mV, n=6. To test the role of gap junctional communication in the gen- 
eration of RMP, we applied 100 pM 18 P_glycarrhytinic acid (ACO; a gap junction 
blocker) to confluent cell cultures. This was shown to block gap junctional communica- 
tlon, as tested with 5% Lucifer yellow microlnjections. After 12 hours of treatment with 
ACO, the membrane potential of confluent cells was completely abolished 0.4 kO.37 mV, 
n=7. To determine that AC0 did not affect membrane channels linked to maintaining 
RMP, we applied AC0 to Neuroblastoma (N2a) cells. In these cells, the RMP does not 
depend on the number of cells grouped a cluster. AC0 did not significantly affect the 
RMP of single (-52.2kO.58 mV; n=6) or confluent (-53.6tO.6 mV; n=5) N2a cells 
AC0 was also shown to reduce cell growth of NRK cells by 75% over 40 hours. 
Conclusions: Generation of RMP in NRK cells depends on the number of cells grouped 
together in a cluster through gap junctions. DisruptIon of this communication abolishes 
RMP, and also reduces cell growth. The intracellular signaling mechanisms involved 
remain to be determined. 
